Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Providers must weigh individual risk-benefit carefully
Phaze keeps them next to your weight and meals, across 8 biomarker categories, with plain-language context
Clinicians advise caution until controlled trials confirm benefits and safety
Trials show up to 20% body weight reduction, raising interest in whether dual incretin pathways may also intersect with estrogen deficiency-driven fat redistribution
Successful weight loss usually does not happen from a single appointment
Retatrutide produces 82-86% reductions in liver fat at 48 weeks, with 89-93% of participants achieving less than 5% liver fat (the threshold for resolution of fatty liver disease)
US$ 29.06
US$ 28.10
US$ 28.58
